Annexin Pharmaceuticals AB (ANNX) - Total Liabilities

Latest as of March 2026: Skr5.56 Million SEK ≈ $598.56K USD

Based on the latest financial reports, Annexin Pharmaceuticals AB (ANNX) has total liabilities worth Skr5.56 Million SEK (≈ $598.56K USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Annexin Pharmaceuticals AB equity growth rate to track the company's year-over-year net asset growth rate.

Annexin Pharmaceuticals AB - Total Liabilities Trend (2014–2025)

This chart illustrates how Annexin Pharmaceuticals AB's total liabilities have evolved over time, based on quarterly financial data.

Annexin Pharmaceuticals AB Competitors by Total Liabilities

The table below lists competitors of Annexin Pharmaceuticals AB ranked by their total liabilities.

Company	Country	Total Liabilities
Reabold Resources Plc LSE:RBD	UK	GBX2.18 Million
Lisata Therapeutics Inc. NASDAQ:LSTA	USA	$4.64 Million
Australian Dairy Nutritionals Ltd AU:AHF	Australia	AU$2.02 Million
Perpetual Resources Ltd AU:PEC	Australia	AU$111.78K
Taitron Components Incorporated NASDAQ:TAIT	USA	$2.02 Million
Aston Bay Holdings Ltd V:BAY	Canada	CA$205.96K
Q Interline AS CO:QINTER	Denmark	Dkr23.87 Million
Kordellos Ch. Bros S.A AT:KORDE	Greece	€38.84 Million

Liability Composition Analysis (2014–2025)

This chart breaks down Annexin Pharmaceuticals AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Annexin Pharmaceuticals AB worth.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	3.31	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	0.39	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.28	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Annexin Pharmaceuticals AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Annexin Pharmaceuticals AB (2014–2025)

The table below shows the annual total liabilities of Annexin Pharmaceuticals AB from 2014 to 2025.

Year	Total Liabilities	Change
2025-12-31	Skr5.22 Million ≈ $562.19K	-1.86%
2024-12-31	Skr5.32 Million ≈ $572.84K	-33.04%
2023-12-31	Skr7.95 Million ≈ $855.44K	+21.81%
2022-12-31	Skr6.53 Million ≈ $702.30K	+7.71%
2021-12-31	Skr6.06 Million ≈ $652.05K	+34.05%
2020-12-31	Skr4.52 Million ≈ $486.42K	-0.59%
2019-12-31	Skr4.55 Million ≈ $489.33K	-26.52%
2018-12-31	Skr6.19 Million ≈ $665.93K	-3.45%
2017-12-31	Skr6.41 Million ≈ $689.71K	-18.72%
2016-12-31	Skr7.88 Million ≈ $848.55K	+140.18%
2015-12-31	Skr3.28 Million ≈ $353.30K	+234.61%
2014-12-31	Skr981.14K ≈ $105.59K	--

About Annexin Pharmaceuticals AB

ST:ANNX Sweden Biotechnology

Market Cap

$9.15 Million

Skr85.06 Million SEK

Market Cap Rank

#27249 Global

#593 in Sweden

Share Price

Skr12.05

Change (1 day)

-1.63%

52-Week Range

Skr12.00 - Skr31.80

All Time High

Skr37.00